AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10639301 — intervention group
Group type: COMPARATOR
Intervention: Low dose amiodarone
Number of subjects: 1073
Study 10639301 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 1073
Study 8878569 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-coated triple-lumen catheters
Number of subjects: 254
Study 8878569 — intervention group
Group type: COMPARATOR
Intervention: Uncoated control catheters
Number of subjects: 254
Study 1505605 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted dosing of theophylline (437 mg loading dose)
Number of subjects: 25
Study 1505605 — intervention group
Group type: COMPARATOR
Intervention: Control group (unaided physicians dosing of theophylline, 167 mg loading dose)
Number of subjects: 25
Study 1505605 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted dosing of theophylline (613 mg loading dose for patients not previously on theophylline)
Number of subjects: 25
Study 1505605 — intervention group
Group type: COMPARATOR
Intervention: Control group (200 mg loading dose for patients not previously on theophylline)
Number of subjects: 25
Study 1505605 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (computer-assisted and control)
Number of subjects: 25
Study 6381556 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride at a dosage of 150 mg at bedtime
Number of subjects: 32
Study 6381556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31168959 — intervention group
Group type: EXPERIMENTAL
Intervention: Influencer marketing of an unhealthy snack with advertising disclosure (n = 50)
Number of subjects: 151
Study 31168959 — intervention group
Group type: EXPERIMENTAL
Intervention: Influencer marketing of an unhealthy snack without advertising disclosure (n = 50)
Number of subjects: 151
Study 31168959 — intervention group
Group type: COMPARATOR
Intervention: Control group (influencer marketing of a non-food product) (n = 51)
Number of subjects: 151
Study 31473805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecc‐vBFR (n=12)
Number of subjects: 25
Study 31473805 — intervention group
Group type: COMPARATOR
Intervention: Con‐vBFR (n=13)
Number of subjects: 25
Study 27980864 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field with nerve and tendon gliding exercises, three times per week for four weeks
Number of subjects: 40
Study 27980864 — intervention group
Group type: COMPARATOR
Intervention: Pulsed ultrasound with the same wrist exercises
Number of subjects: 40
Study 25445859 — intervention group
Group type: EXPERIMENTAL
Intervention: benralizumab (0.3 mg/kg and 1.0 mg/kg)
Number of subjects: 110
Study 25445859 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 110
Study 24071578 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 400-mg oral dose of ribavirin
Number of subjects: 24
Study 20962657 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope (AWS)
Number of subjects: 70
Study 20962657 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 70
Study 19625981 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Effectiveness Therapy for Children
Number of subjects: 88
Study 17261405 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 3998
Study 17261405 — intervention group
Group type: COMPARATOR
Intervention: No Chronic Kidney Disease (CKD)
Number of subjects: 3998
Study 17261405 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Heart Failure (LVEF >45%) with CKD
Number of subjects: 3998
Study 17261405 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Heart Failure (LVEF ≤45%) with CKD
Number of subjects: 3998
Study 17261405 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF <35% with CKD
Number of subjects: 3998
Study 17261405 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF 35% to 55% with CKD
Number of subjects: 3998
Study 17261405 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF >55% with CKD
Number of subjects: 3998
Study 15541237 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding stent after beta-VBT
Number of subjects: 27
Study 15541237 — intervention group
Group type: COMPARATOR
Intervention: Self-expanding stent alone
Number of subjects: 27
Study 11995261 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled heparin
Number of subjects: 14
Study 11995261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9728845 — intervention group
Group type: EXPERIMENTAL
Intervention: IV amino acid infusion at the rate of 126 mL/h throughout anesthesia
Number of subjects: 14
Study 9728845 — intervention group
Group type: COMPARATOR
Intervention: Nutrient‐free saline infusion
Number of subjects: 14
Study 8665279 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuko Ankle brace
Number of subjects: 13
Study 8665279 — intervention group
Group type: EXPERIMENTAL
Intervention: Nessa Ankle brace
Number of subjects: 13
Study 8665279 — intervention group
Group type: COMPARATOR
Intervention: Control (no brace)
Number of subjects: 13
Study 3177911 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 105
Study 3177911 — intervention group
Group type: COMPARATOR
Intervention: Regional anesthesia
Number of subjects: 105
Study 3177911 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia and Regional anesthesia
Number of subjects: 105
Study 31647185 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA treatment (400 U at 12-week intervals)
Number of subjects: 296
Study 30342297 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC polypill (atenolol, ramipril, hydrochlorothiazide, and a statin)
Number of subjects: 5713
Study 30342297 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 5713
Study 30342297 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 5713
Study 30342297 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effect of aspirin and the Polycap
Number of subjects: 5713
Study 30342297 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for aspirin and vitamin D)
Number of subjects: 5713
Study 28103904 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib plus best supportive care (BSC)
Number of subjects: 113
Study 28103904 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 113
Study 28103904 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib (phase Ib study)
Number of subjects: 113
Study 26185179 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg ephedrine, twice daily
Number of subjects: 4
Study 26185179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 23510972 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Structured Rich-Media guidelines (ISRMGs) on mobile phones
Number of subjects: 50
Study 23510972 — intervention group
Group type: COMPARATOR
Intervention: Paper-based guidelines
Number of subjects: 50
Study 21211686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 360
Study 21211686 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 360
Study 19098618 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90
Study 19098618 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 90
Study 19098618 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 90
Study 16814218 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women who gained 40 or more pounds during pregnancy
Number of subjects: 0
Study 16814218 — intervention group
Group type: EXPERIMENTAL
Intervention: Total pregnancy weight gain
Number of subjects: 0
Study 16814218 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant birthweight
Number of subjects: 0
Study 16814218 — intervention group
Group type: COMPARATOR
Intervention: Intrapartum care measures and labor events
Number of subjects: 0
Study 12736880 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (14 months of vigorous, combined high-impact, strength, and endurance training)
Number of subjects: 100
Study 12736880 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 100
Study 12736880 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 100
Study 12736880 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 11003446 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass-pollen immunotherapy
Number of subjects: 52
Study 11003446 — intervention group
Group type: COMPARATOR
Intervention: Birch-pollen immunotherapy
Number of subjects: 52
Study 11003446 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 52
Study 9087388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injections of lymphokine-activated killer (LAK) cells (2 to 9 x 10^8) and recombinant interleukin-2 (rIL-2) (10^6 IU) weekly for four cycles, plus subcutaneous rIL-2 (3 x 10^6 IU/day for 24 days)
Number of subjects: 9
Study 7968328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg sublingual)
Number of subjects: 33
Study 7968328 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33
Study 7968328 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine and Control group
Number of subjects: 33
Study 6117466 — intervention group
Group type: EXPERIMENTAL
Intervention: Strophanthin (0.5 mg)
Number of subjects: 10
Study 6117466 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol (10 mg)
Number of subjects: 10
Study 6117466 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (4 mg)
Number of subjects: 10
Study 6117466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6117466 — intervention group
Group type: EXPERIMENTAL
Intervention: Strophanthin compared to β-blockers (Practolol and Propranolol)
Number of subjects: 10
Study 6117466 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol and Propranolol
Number of subjects: 10
Study 6117466 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs (Strophanthin, Practolol, Propranolol)
Number of subjects: 10
Study 31336450 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D plus physical activity
Number of subjects: 70
Study 31336450 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 70
Study 31336450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 28816136 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 78
Study 28816136 — intervention group
Group type: COMPARATOR
Intervention: No Music Therapy (no-MT)
Number of subjects: 78
Study 26017676 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfer (UCT)
Number of subjects: 5331
Study 26017676 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfer (CCT)
Number of subjects: 5331
Study 26017676 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 5331
Study 26017676 — intervention group
Group type: EXPERIMENTAL
Intervention: Household Assets
Number of subjects: 5331
Study 23577700 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care package with reduced visits
Number of subjects: 12568
Study 23577700 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 12568
Study 21228786 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg per day)
Number of subjects: 201
Study 21228786 — intervention group
Group type: COMPARATOR
Intervention: Perindopril/Indapamide (2/0.6 mg per day)
Number of subjects: 201
Study 19856795 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug (500 mg azithromycin tablet - Zycin)
Number of subjects: 18
Study 19856795 — intervention group
Group type: COMPARATOR
Intervention: Reference drug (500 mg azithromycin)
Number of subjects: 18
Study 19856795 — intervention group
Group type: COMPARATOR
Intervention: Test drug (500 mg azithromycin tablet - Zycin) vs Reference drug (500 mg azithromycin)
Number of subjects: 18
Study 17215752 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum TENS
Number of subjects: 63
Study 17215752 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS (Control)
Number of subjects: 63
Study 17145426 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500 IU of dalteparin subcutaneously for 3 months plus 100 mg of aspirin daily (n = 137)
Number of subjects: 275
Study 17145426 — intervention group
Group type: COMPARATOR
Intervention: 100 mg aspirin daily alone (n = 138)
Number of subjects: 275
Study 14523634 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 306
Study 14523634 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 306
Study 14523634 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 306
Study 10618674 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian group
Number of subjects: 41
Study 10618674 — intervention group
Group type: EXPERIMENTAL
Intervention: Afro-Caribbean group
Number of subjects: 41
Study 10618674 — intervention group
Group type: COMPARATOR
Intervention: Caucasian group (adjusted for blood pressure)
Number of subjects: 41
Study 7545577 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 12 IU/m2 per week
Number of subjects: 39
Study 7545577 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 18 IU/m2 per week
Number of subjects: 39
Study 7545577 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (Ox) after GH treatment
Number of subjects: 39
Study 7545577 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) after GH treatment
Number of subjects: 39
Study 1963014 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (30 mg subcutaneously twice daily for 14 days)
Number of subjects: 100
Study 1963014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 6217577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg/day) for one month
Number of subjects: 20
Study 6217577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31619653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-High Hydrostatic Pressurizing Brown Rice (UHHPBR)
Number of subjects: 52
Study 31619653 — intervention group
Group type: COMPARATOR
Intervention: Polished White Rice (WR)
Number of subjects: 52
Study 27999106 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐h overnight GCG infusion (6 ng/[kg × min]) followed by 3‐h infusion of GCG, octreotide (OCT), and insulin (INS)
Number of subjects: 30
Study 27999106 — intervention group
Group type: COMPARATOR
Intervention: Overnight saline (SAL) infusion followed by GCG/OCT/INS infusion
Number of subjects: 30
Study 27999106 — intervention group
Group type: COMPARATOR
Intervention: Overnight saline (SAL) infusion followed by SAL/OCT/INS infusion
Number of subjects: 30
Study 25260112 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% maximum voluntary handgrip contraction
Number of subjects: 55
Study 25260112 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% maximum voluntary handgrip contraction
Number of subjects: 55
Study 25260112 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% maximum voluntary handgrip contraction
Number of subjects: 55
Study 25260112 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 23448122 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure laparoscopic cholecystectomy (HPLC) at 14 mm Hg
Number of subjects: 101
Study 23448122 — intervention group
Group type: COMPARATOR
Intervention: Low-pressure laparoscopic cholecystectomy (LPLC) at 8 mm Hg
Number of subjects: 101
Study 21255431 — intervention group
Group type: EXPERIMENTAL
Intervention: Iyengar yoga program (12 - 1.5 hour sessions twice weekly for 6 weeks)
Number of subjects: 70
Study 21255431 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 70
Study 18050059 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (20-week progressive strength training)
Number of subjects: 74
Study 18050059 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 74
Study 16801514 — intervention group
Group type: COMPARATOR
Intervention: Prefabricated orthosis (firm foam)
Number of subjects: 135
Study 16801514 — intervention group
Group type: COMPARATOR
Intervention: Customized orthosis (semirigid plastic)
Number of subjects: 135
Study 16801514 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham orthosis (soft, thin foam)
Number of subjects: 135
Study 12708641 — intervention group
Group type: EXPERIMENTAL
Intervention: CT screening
Number of subjects: 0
Study 12708641 — intervention group
Group type: COMPARATOR
Intervention: Chest X-ray screening
Number of subjects: 0
Study 12708641 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 0
Study 10914850 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic, weight bearing exercise program (3 times a week for 12 months)
Number of subjects: 30
Study 10914850 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 10914850 — intervention group
Group type: COMPARATOR
Intervention: Steroid treated groups (exercise vs usual care)
Number of subjects: 30
Study 8616076 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous monoclonal IgG immunization
Number of subjects: 5
Study 8616076 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated immunization
Number of subjects: 5
Study 1451521 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic ethinylestradiol (EE)/desogestrel (DSG) OC
Number of subjects: 37
Study 1451521 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic levonorgestrel (LNG) OC
Number of subjects: 37
Study 1451521 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic levonorgestrel (LNG) OC
Number of subjects: 37
Study 1451521 — intervention group
Group type: EXPERIMENTAL
Intervention: All OCs
Number of subjects: 37
Study 1451521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical symptom changes
Number of subjects: 37
Study 1451521 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with 'pure' PMS
Number of subjects: 37
Study 6364395 — intervention group
Group type: EXPERIMENTAL
Intervention: specially designed infant milk formula
Number of subjects: 0
Study 6364395 — intervention group
Group type: COMPARATOR
Intervention: standard modified infant milk formula
Number of subjects: 0
Study 30506103 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mindfulness-based intervention (MBI)
Number of subjects: 69
Study 30506103 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 69
Study 29749363 — intervention group
Group type: EXPERIMENTAL
Intervention: Unani treatment (oral UNIM-401 and topical UNIM-403)
Number of subjects: 287
Study 29749363 — intervention group
Group type: COMPARATOR
Intervention: PUVA sol
Number of subjects: 287
Study 27528849 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad with video
Number of subjects: 146
Study 27528849 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad with game
Number of subjects: 146
Study 27528849 — intervention group
Group type: COMPARATOR
Intervention: no-iPad
Number of subjects: 146
Study 24452673 — intervention group
Group type: COMPARATOR
Intervention: Sequential induction chemotherapy and radiotherapy (control)
Number of subjects: 450
Study 24452673 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemoradiotherapy (experimental)
Number of subjects: 450
Study 20971655 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD with cholinergic involvement (CVD-Ch(+))
Number of subjects: 502
Study 20971655 — intervention group
Group type: COMPARATOR
Intervention: Non-CVD
Number of subjects: 502
Study 20971655 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD without cholinergic involvement (CVD-Ch(-))
Number of subjects: 502
Study 20129231 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention aimed at portion control
Number of subjects: 19
Study 20129231 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 19
Study 20129231 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-weighing (regardless of group)
Number of subjects: 19
Study 17331860 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 165
Study 17331860 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 165
Study 17331860 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 165
Study 16280436 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 164
Study 16280436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 11689274 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard
Number of subjects: 436
Study 11689274 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 436
Study 9463180 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/day for 6 months)
Number of subjects: 80
Study 9463180 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg twice daily for 6 months)
Number of subjects: 80
Study 7949640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (n = 6)
Number of subjects: 41
Study 7949640 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (n = 13)
Number of subjects: 41
Study 7949640 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (n = 15)
Number of subjects: 41
Study 7949640 — intervention group
Group type: COMPARATOR
Intervention: 7% sodium bicarbonate (n = 7)
Number of subjects: 41
Study 3079582 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow excision (1-cm margins)
Number of subjects: 612
Study 3079582 — intervention group
Group type: COMPARATOR
Intervention: Wide excision (3-cm margins)
Number of subjects: 612
Study 29659631 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1 gram) IV preoperatively followed by two postoperative doses 6 hours apart
Number of subjects: 50
Study 29659631 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 50
Study 29659631 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1 gram) IV
Number of subjects: 50